Study of a High-Dose Aflibercept in Participants With Diabetic Eye Disease

Key Inclusion Criteria:

• Diabetic macular edema (DME) with central involvement in the study eye

• Best corrected visual acuity (BCVA) early treatment diabetic retinopathy study (ETDRS) letter score of 78 to 24 (approximate Snellen equivalent of 20/32 to 20/320)in the study eye with decreased vision determined to be primarily the result of DME

• Willing and able to comply with clinic visits and study-related procedures

• Provide informed consent signed by study participant or legally acceptablerepresentative

Extension Phase: All randomized patients that complete visit 26, week 96, as long as the patient 1) provides informed consent and 2) no treatment for DME has been given in the study eye other than the randomized study treatment.

Key Exclusion Criteria:

• Evidence of macular edema due to any cause other than diabetes mellitus in eithereye

• Active proliferative diabetic retinopathy in the study eye

• IVT anti-VEGF treatment (aflibercept, ranibizumab, bevacizumab, brolucizumab,pegaptanib sodium) or panretinal laser photocoagulation (PRP) /macular laserphotocoagulation within 12 weeks (84 days) or intraocular or periocularcorticosteroids within 16 weeks (112 days) of the screening visit in the study eye

• Prior IVT investigational agents in either eye (eg, anti-ang-2/anti-VEGF bispecificmonoclonal antibodies, gene therapy, etc.) at any time

• Treatment with ocriplasmin (JETREA®) in the study eye at any time

NOTE: Other Protocol Defined Inclusion/Exclusion Criteria Apply